Ensure and Similac could become part of a new company as Abbott plans a split.

Abbott Laboratories (ABT) plans to spin off its Nutrition business, including brands like Similac, into a separate publicly traded company. The announcement came ahead of its Q3 2026 earnings, and the stock slipped on the news.

Abbott (ABT) plans to spin off its Nutrition business into a separate, publicly traded company by late 2027. Daniel Salvadori will lead the new entity, which will have 16,000 employees and 14 manufacturing sites. Abbott expects to incur one-time charges but reassures that the separation won't affect its 2026 or 2027 guidance. Pre-market trading shows ABT shares down 3.61% to $98.99.

Abbott Laboratories reported Q3 2026 revenue of $13.01B, up 14.5% YoY, and adjusted EPS of $1.42. The company reaffirmed FY 2026 adjusted EPS guidance of $5.50-$5.55 and projected 6% sales growth. Notable segment performances included Diagnostics (+6.4%) and Medical Devices (+7.8%). Abbott also announced new product approvals and declared a $0.63 quarterly dividend.

Abbott (ABT) reported Q3 2026 revenue of $13.013B, up 14.5% YoY, with GAAP EPS falling to $0.53 from $0.94. The company reaffirmed its adjusted EPS guidance range of $5.50-$5.55. Medical Devices sales rose 6.9%, Diagnostics 46.7%, Nutrition 5.1%, and Established Pharmaceuticals 6.8%.

Abbott Laboratories (ABT) reported Q3 net income of $920M, or 53 cents per share, missing estimates. Adjusted EPS was $1.42, below the $1.43 expected. Revenue was $13.01B, exceeding forecasts. The company expects Q4 EPS of $1.62-$1.67 and full-year EPS of $5.50-$5.55. ABT shares are down 18% YTD.

Abbott (NYSE:ABT) reported Q3 adjusted EPS of $1.42, meeting estimates, and revenue of $13.01B, slightly above consensus. Shares fell 1.4% premarket after announcing plans to spin off its Nutrition unit by 2027. The company reaffirmed its full-year 2026 adjusted EPS guidance, tightening it to $5.50-$5.55. Medical Devices and Diagnostics segments drove growth.